KR20230109286A - Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea - Google Patents
Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea Download PDFInfo
- Publication number
- KR20230109286A KR20230109286A KR1020220005067A KR20220005067A KR20230109286A KR 20230109286 A KR20230109286 A KR 20230109286A KR 1020220005067 A KR1020220005067 A KR 1020220005067A KR 20220005067 A KR20220005067 A KR 20220005067A KR 20230109286 A KR20230109286 A KR 20230109286A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin
- black
- photodamage
- lotion
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 241000561705 Kadsura coccinea Species 0.000 title claims abstract description 17
- 206010051246 Photodermatosis Diseases 0.000 title description 2
- 210000003491 skin Anatomy 0.000 claims abstract description 43
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 30
- 230000008832 photodamage Effects 0.000 claims abstract description 30
- 230000004224 protection Effects 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 241000282988 Capreolus Species 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- -1 foundation Substances 0.000 claims description 8
- 230000003796 beauty Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000003834 intracellular effect Effects 0.000 abstract description 11
- 230000035899 viability Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000030833 cell death Effects 0.000 abstract description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 12
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 150000002215 flavonoids Chemical class 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000010609 cell counting kit-8 assay Methods 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003711 photoprotective effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000036559 skin health Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102100033299 Glia-derived nexin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000029411 keratinocyte apoptotic process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000008014 pharmaceutical binder Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008039 pharmaceutical dispersing agent Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 흑노호 추출물을 포함하는 피부 광손상 보호용 조성물에 관한 것으로, 흑노호(Kadsura coccinea) 부위별 추출물, 특히 흑노호 잎 추출물이 UVA 및 UVB 조사가 있는 상태에서 각질세포 생존력을 개선하고 LDH 방출, 세포 내 ROS 생성 및 세포사멸을 감소시켜 피부 광손상 보호 효과를 나타내므로, 피부 광손상 보호용 의약품, 화장품, 건강기능식품 등 다양하게 활용될 수 있다.The present invention relates to a composition for skin photodamage protection comprising an extract of black oenophila, wherein the extract of each part of Kadsura coccinea, particularly the leaf extract of black oenophila, improves keratinocyte viability and releases LDH in the presence of UVA and UVB irradiation , It reduces intracellular ROS generation and cell death to show skin photodamage protection effects, so it can be used in various ways such as medicines for skin photodamage protection, cosmetics, and health functional foods.
Description
본 발명은 흑노호 추출물을 포함하는 피부 광손상 보호용 조성물에 관한 것이다.The present invention relates to a composition for protecting skin from photodamage comprising a black oatmeal extract.
UVA(320-400 nm), UVB(280-320 nm), UVC(100-280 nm)를 특징으로 하는 태양 자외선(UV)은 세포독성, 유전독성 및 광독성으로 인한 피부암 및 광노화를 유발하는 가장 중요한 환경적 요인이다. 구체적으로 UVA와 UVB는 일일 UV 조사량의 각각 95% 이상과 3% 이상을 차지하며, UVA 및 UVB 조사는 피부의 표피 및/또는 진피층에 침투하여 활성 산소종(ROS)을 간접적으로 또는 직접적으로 유도하여 산화적 손상 및 세포 사멸을 유발할 수 있다. Solar ultraviolet (UV), characterized by UVA (320-400 nm), UVB (280-320 nm), and UVC (100-280 nm), is the most important cause of skin cancer and photoaging due to cytotoxicity, genotoxicity and phototoxicity. is an environmental factor. Specifically, UVA and UVB account for more than 95% and more than 3% of daily UV irradiation, respectively, and UVA and UVB irradiation penetrate the epidermal and/or dermal layers of the skin to indirectly or directly induce reactive oxygen species (ROS). This can cause oxidative damage and cell death.
최근 수십 년 동안 UV 조사는 심각한 피부 건강 문제가 되었으며 여전히 전 세계적으로 위험하게 확산되고 있으며, 피부 표피 세포 질량의 약 95%를 차지하는 각질세포에 대한 직접적이고 일관된 자극제로 알려져 있다. 각질세포는 미생물, 화학적 및 물리적 위험에 대한 첫 번째 장벽 역할을 하며 UVA 및 UVB 조사에 대한 방어에 도움이 된다. 각질세포가 UVA 및 UVB에 노출되면 세포 내 ROS가 생성되어 세포자멸사를 유발하는 것으로 알려져 있다.In recent decades, UV irradiation has become a serious skin health problem and is still spreading dangerously worldwide, and is known as a direct and consistent irritant to keratinocytes, which account for about 95% of the skin's epidermal cell mass. Keratinocytes act as the first barrier to microbial, chemical and physical hazards and help defend against UVA and UVB irradiation. It is known that when keratinocytes are exposed to UVA and UVB, intracellular ROS are generated to induce apoptosis.
한편, 흑노호(Kadsura coccinea (Lem.) B.C. Sm)는 중국에서 "검은 호랑이"라고도 알려진 경제적으로나 의학적으로 중요한 오미자과에 속하는 종으로, 주로 중국 남부, 태국, 한국에서 재배되며, 여러 질병을 예방하기 위한 중국 민간 요법으로 관심을 갖게 되었다. 식품으로 섭취할 뿐만 아니라 약리학적 특성, 특히 항HIV, 항진균, 항지질 과산화, 항간염, 항염, 항종양 활성이 알려져 있다. 또한, 다수의 연구에서 위장 장애 및 류마티스 관절염 치료, 심장 진정, 신장 강화, 혈액 및 체액 순환 촉진과 같은 치료 효과를 확인한 바 있다. On the other hand, Kadsura coccinea (Lem.) BC Sm) is an economically and medically important species belonging to Schizandra chinensis, also known as "black tiger" in China, and is mainly cultivated in southern China, Thailand, and Korea, and is used to prevent various diseases. became interested in Chinese folk remedies for In addition to being consumed as food, pharmacological properties, especially anti-HIV, anti-fungal, anti-lipid peroxidation, anti-hepatitis, anti-inflammatory and anti-tumor activity are known. In addition, many studies have confirmed therapeutic effects such as treating gastrointestinal disorders and rheumatoid arthritis, soothing the heart, strengthening the kidneys, and promoting blood and body fluid circulation.
그러나, 아직까지 흑노호 추출물을 이용한 피부 광보호 효과에 대해서는 전혀 알려진 바 없으며, 심각한 피부 건강 문제를 야기하는 UV 조사에 대한 피부 각질세포의 방어를 위한 새로운 치료제 개발이 필요한 실정이다.However, the skin photoprotection effect using the black oenophile extract has not been known at all, and it is necessary to develop a new treatment for the defense of skin keratinocytes against UV irradiation that causes serious skin health problems.
본 발명의 목적은 심각한 피부 건강 문제를 야기하는 UV 조사에 대한 피부 각질세포의 방어를 위한 새로운 치료제 개발을 통한 피부 광보호용 조성물을 제공하는 데에 있다.An object of the present invention is to provide a composition for skin photoprotection through the development of a new therapeutic agent for the defense of skin keratinocytes against UV irradiation that causes serious skin health problems.
본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for protecting skin from photodamage comprising Kadsura coccinea extract.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 화장료조성물을 제공한다.In addition, the present invention provides a cosmetic composition for protecting skin from photodamage comprising Kadsura coccinea extract.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for skin photodamage protection containing Kadsura coccinea extract.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 외용제를 제공한다.In addition, the present invention provides an external preparation for skin photodamage protection containing Kadsura coccinea extract.
본 발명에 따르면, 흑노호(Kadsura coccinea) 부위별 추출물, 특히 흑노호 잎 추출물이 UVA 및 UVB 조사가 있는 상태에서 각질세포 생존력을 개선하고 LDH 방출, 세포 내 ROS 생성 및 세포사멸을 감소시켜 피부 광손상 보호 효과를 나타내므로, 피부 광손상 보호용 의약품, 화장품, 건강기능식품 등 다양하게 활용될 수 있다.According to the present invention, extracts of black roe deer ( Kadsura coccinea ) parts, especially black roe leaf extracts, improve keratinocyte viability in the presence of UVA and UVB irradiation and reduce LDH release, intracellular ROS production and apoptosis, thereby reducing skin light Since it shows a damage protection effect, it can be used in various ways such as medicines for skin photodamage protection, cosmetics, and health functional foods.
도 1은 흑노호 부위별 추출물의 항산화 효과를 나타낸 것으로, (A) 흑노호 각 부위별 사진, (B) 총 폴리페놀 함량, (C) 플라보노이드 함량, (D) ABTS 라디칼 소거 활성 및 (E) DPPH 라디칼 소거 활성을 각각 나타낸다.
도 2는 UVA 또는 UVB 조사에 의한 각질세포의 생존율과 세포독성에 대한 흑노호 부위별 추출물의 광손상 보호 효과를 나타낸다.
도 3은 UVA 또는 UVB 조사에 의한 각질세포 내 ROS 생성에 대한 흑노호 부위별 추출물의 광손상 보호 효과를 나타낸다.
도 4는 UVA 또는 UVB 조사에 의한 세포자멸사에 대한 흑노호 부위별 추출물의 광손상 보호 효과를 나타낸다.Figure 1 shows the antioxidant effect of extracts of black roe deer parts, (A) pictures of each part of black roe deer, (B) total polyphenol content, (C) flavonoid content, (D) ABTS radical scavenging activity, and (E) DPPH radical scavenging activity, respectively.
Figure 2 shows the photodamage protection effect of the extract for each part of black oatmeal on the survival rate and cytotoxicity of keratinocytes by UVA or UVB irradiation.
Figure 3 shows the photodamage protection effect of extracts by parts of black oatmeal on ROS generation in keratinocytes by UVA or UVB irradiation.
Figure 4 shows the photodamage protection effect of the extract of each part of black oatmeal against apoptosis by UVA or UVB irradiation.
이하에서는 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 발명자는 피부 광손상을 예방하거나 치료할 수 있는 물질 개발에 예의 노력한 결과, 흑노호(Kadsura coccinea) 부위별 추출물, 특히 흑노호 잎 추출물이 UVA 및 UVB 조사가 있는 상태에서 각질세포 생존력을 개선하고 LDH 방출, 세포 내 ROS 생성 및 세포사멸을 감소시켜 피부 광손상 보호 효과를 나타내는 것을 밝혀 냄으로써, 본 발명을 완성하였다.The inventors of the present invention have made diligent efforts to develop materials capable of preventing or treating skin photodamage, and as a result, extracts for each part of Kadsura coccinea , especially black roe leaf extracts, improve the viability of keratinocytes in the presence of UVA and UVB irradiation. The present invention was completed by revealing that the LDH release, intracellular ROS production and apoptosis were reduced to exhibit skin photodamage protection effects.
이에, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 약학조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for skin photodamage protection containing Kadsura coccinea extract.
상기 흑노호 추출물은 흑노호의 잎, 뿌리, 줄기 또는 열매 중 어느 하나 이상을 물, C1~C4 알코올 또는 이들의 혼합용액으로 추출할 수 있지만, 이에 한정되는 것은 아니다.The black oenophile extract may be extracted from at least one of leaves, roots, stems, or fruits of black oenophile with water, C1 to C4 alcohol, or a mixed solution thereof, but is not limited thereto.
상기 흑노호 추출물은 자외선에 대한 각질세포 보호 활성을 갖는다. 특히, 흑노호 추출물은 총 폴리페놀 및 플라보노이드 함량이 높고, 라디칼 소거 활성을 나타내며, 자외선 조사가 있는 상태에서 각질 세포 생존력을 개선하고 LDH 방출, 세포 내 ROS 생성 및 세포 사멸을 감소시킬 수 있으며, 이러한 흑노호 추출물의 피부 광손상 보호 효과는 흑노호 잎 추출물, 흑노호 뿌리 추출물, 흑노호 줄기 추출물 및 흑노호 열매 추출물 순으로 우수한 피부 광손상 보호 효과를 나타낸다.The black roe extract has a keratinocyte protective activity against ultraviolet rays. In particular, black roe extract has high total polyphenol and flavonoid content, shows radical scavenging activity, can improve keratinocyte viability in the presence of ultraviolet irradiation and reduce LDH release, intracellular ROS production and cell death, The skin photodamage protection effect of the black oenophile extract shows the excellent skin photodamage protection effect in the order of the black oko leaf extract, the black oko root extract, the black oko locust stem extract, and the black oko locust fruit extract.
상기 약학조성물은 통상적인 방법에 따라 겔제, 유제, 주사제, 산제, 과립제, 에어로솔제, 페이스트제, 경피흡수제 및 패치제로 이루어진 군에서 선택된 하나 이상의 제형으로 제공될 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition may be provided in one or more formulations selected from the group consisting of gels, emulsions, injections, powders, granules, aerosols, pastes, percutaneous absorbents, and patches according to conventional methods, but is not limited thereto.
본 발명의 다른 구체예에서, 상기 약학조성물은 약학조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제, 붕해제, 감미제, 피복제, 팽창제, 윤활제, 활택제, 향미제, 항산화제, 완충액, 정균제, 희석제, 분산제, 계면활성제, 결합제 및 윤활제로 이루어진 군에서 선택되는 하나 이상의 첨가제를 추가로 포함할 수 있다.In another embodiment of the present invention, the pharmaceutical composition is a suitable carrier, excipient, disintegrant, sweetener, coating agent, expanding agent, lubricant, lubricant, flavoring agent, antioxidant, buffer, bacteriostatic agent commonly used in the preparation of pharmaceutical compositions , Diluents, dispersants, surfactants, binders and may further include one or more additives selected from the group consisting of lubricants.
구체적으로 담체, 부형제 및 희석제는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 사용할 수 있으며, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제할 수 있다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용할 수 있다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 있으며 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제 등이 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기재로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Specifically, carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil may be used, and solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules. These solid preparations may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the composition. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions for oral use, emulsions, syrups, and the like, and various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base material of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
상기 약학조성물은 정맥내, 동맥내, 복강내, 근육내, 동맥내, 복강내, 흉골내, 경피, 비측내, 흡입, 국소, 직장, 경구, 안구내 또는 피내 경로를 통해 통상적인 방식으로 대상체로 투여할 수 있다.The pharmaceutical composition is administered to a subject in a conventional manner through intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal routes. can be administered with
상기 흑노호 추출물의 바람직한 투여량은 대상체의 상태 및 체중, 질환의 종류 및 정도, 약물 형태, 투여경로 및 기간에 따라 달라질 수 있으며 당업자에 의해 적절하게 선택될 수 있다. 본 발명의 일실시예에 따르면 이에 제한되는 것은 아니지만 1일 투여량이 1 내지 1000 mg/kg, 구체적으로는 10 내지 500 mg/kg일 수 있다. 투여는 하루에 한 번 투여할 수도 있고 수회로 나누어 투여할 수도 있으며, 이에 의해 본 발명의 범위가 제한되는 것은 아니다.The preferred dosage of the black oenophile extract may vary depending on the condition and weight of the subject, the type and severity of the disease, the type of drug, the route and duration of administration, and may be appropriately selected by a person skilled in the art. According to one embodiment of the present invention, although not limited thereto, the daily dosage may be 1 to 1000 mg/kg, specifically 10 to 500 mg/kg. Administration may be administered once a day or divided into several administrations, and the scope of the present invention is not limited thereby.
본 발명에 있어서, 상기 '대상체'는 인간을 포함하는 포유동물일 수 있으나, 이들 예에 한정되는 것은 아니다.In the present invention, the 'subject' may be a mammal including a human, but is not limited to these examples.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 화장료조성물을 제공한다.In addition, the present invention provides a cosmetic composition for protecting skin from photodamage comprising Kadsura coccinea extract.
본 발명에 따른 화장료조성물은 당업계의 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있고, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 밀크로션, 모이스쳐로션, 영양로션, 맛사지크림, 영양크림, 모이스쳐크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클렌저로 이루어진 군에서 선택된 제형으로 제공될 수 있지만, 이에 한정되는 것은 아니다.The cosmetic composition according to the present invention can be prepared in any formulation conventionally manufactured in the art, skin lotion, skin softener, skin toner, astringent, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture It may be provided in a formulation selected from the group consisting of cream, hand cream, foundation, essence, nutrient essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
상기 화장료조성물은 상기 흑노호 추출물 외에 화장료 제제에 있어서 수용 가능한 담체를 포함할 수 있다. 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 방부제, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료, 희석제 등이 포함될 수 있다. 상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 방부제, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료, 희석제 등으로 사용될 수 있는 구체적인 화합물 또는 조성물은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 화합물 또는 조성물을 선택하여 사용할 수 있다.The cosmetic composition may include a carrier acceptable in cosmetic formulations in addition to the black oenophile extract. The carrier may include alcohol, oil, surfactant, fatty acid, silicone oil, preservative, humectant, humectant, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, diluent, and the like. Specific compounds or compositions that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, preservative, humectant, humectant, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, diluent, etc. are already known in the art. Therefore, those skilled in the art can select and use an appropriate compound or composition.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for skin photodamage protection containing Kadsura coccinea extract.
본 발명에서 "건강기능식품"이라 함은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, "functional health food" means a food manufactured and processed using raw materials or ingredients having useful functionality for the human body in accordance with the Health Functional Food Act, and "functional" refers to the structure and function of the human body. It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients for functions or physiological functions.
본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional food of the present invention may include conventional food additives, and the suitability as the "food additive" is determined according to the general rules of the food additive code approved by the Ministry of Food and Drug Safety and general test methods, etc., unless otherwise specified. It is judged according to the standards and standards for the relevant item.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.Items listed in the "Food Additive Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, goyang pigment, guar gum, and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
본 발명의 건강기능식품은 정제, 캡슐, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다. 예를 들어, 캡슐 형태의 건강기능 식품 중 경질캡슐제는 통상의 경질캡슐에 본 발명에 따른 조성물을 부형제 등의 첨가제와 혼합 및 충진하여 제조할 수 있으며, 연질캡슐제는 본 발명에 따른 조성물을 부형제 등의 첨가제와 혼합하고 젤라틴 등 캡슐기제에 충진하여 제조할 수 있다. 상기 연질캡슐제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다. 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다. 상기 식품의 종류에는 특별한 제한이 없으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다. The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like. For example, among the health functional foods in the form of capsules, hard capsules can be prepared by mixing and filling the composition according to the present invention with additives such as excipients in conventional hard capsules, and soft capsules contain the composition according to the present invention. It can be prepared by mixing with additives such as excipients and filling in a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. Definitions of terms for the excipients, binders, disintegrants, lubricants, corrigents, flavoring agents, etc. are described in literature known in the art, and include those having the same or similar functions. There is no particular limitation on the type of food, and it includes all health functional foods in the usual sense.
상기 건강기능식품은 이너뷰티 푸드(inner beauty food) 형태로 섭취함으로써 더욱 우수한 피부 광손상 보호 효과를 나타낼 수 있다. 상기 이너뷰티(inner beauty)는"먹는 화장품 또는 뷰티푸드"로 일컬어지는 이너뷰티 푸드로, 피부에 좋은 여러 가지 성분을 몸속으로 흡수시켜 피부 체질을 건강하게 바꾸는 식품을 지칭하며, 피부 타입에 맞는 화장품을 고르듯 피부 컨디션과 라이프스타일을 고려해 개개인에게 맞는 이너뷰티 푸드를 선택하여 섭취할 수 있다. 보다 바람직하게는 상기 화장료조성물을 포함하는 화장품과 상기 흑노호 추출물을 포함하는 이너뷰티 푸드를 혼용할 경우, 화장품만 사용하는 것에 비해 피부 광손상 보호 효과가 월등히 높아져 더욱 효과적인 피부 광손상 보호 효과를 볼 수 있는 장점을 가진다.The health functional food can exhibit a more excellent skin photodamage protection effect by ingesting it in the form of inner beauty food. The inner beauty is an inner beauty food referred to as "eating cosmetics or beauty food", which refers to food that changes the skin constitution to be healthy by absorbing various ingredients good for the skin into the body, and cosmetics suitable for the skin type. You can select and consume inner beauty food that suits each individual by considering skin condition and lifestyle. More preferably, when the cosmetics containing the cosmetic composition and the inner beauty food containing the black roe extract are mixed, the skin photodamage protection effect is significantly increased compared to using only cosmetics, so that a more effective skin photodamage protection effect can be seen. has the advantage of
본 발명에서 용어 "예방"이란 본 발명에 따른 조성물의 투여로 질환의 억제 또는 지연시키는 모든 행위를 말한다. 본 발명에서 용어 "치료"는 본 발명에 따른 조성물의 투여로 질환의 증세가 호전되거나 이롭게 변경하는 모든 행위를 말한다. 본 발명에서 "개선"이란 본 발명의 조성물을 개체에 투여하거나 섭취시켜 질환의 나쁜 상태를 좋게 하는 모든 행위를 의미한다.In the present invention, the term "prevention" refers to all activities that suppress or delay a disease by administering the composition according to the present invention. In the present invention, the term "treatment" refers to all activities that improve or beneficially change the symptoms of a disease by administering the composition according to the present invention. In the present invention, "improvement" means any action that improves the bad condition of a disease by administering or ingesting the composition of the present invention to a subject.
또한, 본 발명은 흑노호(Kadsura coccinea) 추출물을 포함하는 피부 광손상 보호용 외용제를 제공한다.In addition, the present invention provides an external preparation for skin photodamage protection containing Kadsura coccinea extract.
상기 외용제는 연고제, 크림, 젤, 패취, 분무제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제로 이루어진 군에서 선택된 제형으로 제공될 수 있지만, 이에 한정되는 것은 아니다.The external preparation may be provided in a formulation selected from the group consisting of ointments, creams, gels, patches, sprays, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents, but is not limited thereto.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it is to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. It will be self-evident.
<실시예 1> 흑노호 추출물 제조<Example 1> Preparation of black roe extract
울산의 농가 하우스에서 9L 플라스틱 화분에 3년생 흑노호를 양액의 전도도가 1.0 mSㅇcm-1이고, 무기성분 [NO3-N, 16; NH4-N, 1.34; P, 4; K, 8; Ca, 8; 및 S, 4; 단위: me·L-1]을 포함하는 완전한 영양액을 사용하여 충분히 물을 주었다. 화분에서 자란 흑노호는 2020년 12월에 뿌리, 줄기, 잎, 열매로 구분하여 수확하였다(도 1A). 채취한 시료는 즉시 동결건조기에서 동결건조하고 분석할 때까지 -20℃에서 비닐백에 보관하였다. 흑노호의 건조된 뿌리, 줄기, 잎 및 열매 각 20g를 고운 분말로 분쇄하고 상온에서 에틸알코올(EtOH)로 추출하였다. 흑노호의 EtOH 추출물의 여과 및 증발은 45℃에서 감압하에 수행된 후 동결건조되었다. 마지막으로, 이후 실험을 위해 고체 추출물(50 mg/mL)을 디메틸 설폭사이드(DMSO)에 용해시켰다.In a farm house in Ulsan, the conductivity of the nutrient solution of 3-year-old black roe in a 9L plastic pot is 1.0 mS ㅇ cm -1 , and the inorganic components [NO 3 -N, 16; NH 4 -N, 1.34; P, 4; K, 8; Ca, 8; and S, 4; Unit: me·L -1 ] was sufficiently watered using a complete nutrient solution. Black roe grown in pots was harvested in December 2020 by dividing into roots, stems, leaves, and fruits (Fig. 1A). The collected samples were immediately lyophilized in a lyophilizer and stored in plastic bags at -20 ° C until analysis. 20 g of each of the dried roots, stems, leaves and fruits of black oatmeal were pulverized into a fine powder and extracted with ethyl alcohol (EtOH) at room temperature. Filtration and evaporation of the EtOH extract of black oatmeal were carried out at 45° C. under reduced pressure, followed by lyophilization. Finally, the solid extract (50 mg/mL) was dissolved in dimethyl sulfoxide (DMSO) for further experiments.
<실시예 2> 흑노호 추출물의 총페놀 및 플라보노이드 함량 분석<Example 2> Analysis of total phenolic and flavonoid content of black ocher extract
실시예 1에서 준비된 흑노호 뿌리, 줄기, 잎 및 열매 추출물의 총 폴리페놀 및 플라보노이드 함량은 Folin-Ciocalteu(총 폴리페놀) 및 알루미늄 클로라이드(플라보노이드) 비색법을 사용하여 측정되었다. 흡광도는 Ultrospec 6300 Pro(GE Healthcare Life Sciences, Buckinghamshire, UK)를 사용하여 700 nm(총 폴리페놀)에서 측정하고 VICTOR Multilabel Plate Reader(Perkin-Elmer, Waltham, MA, USA)를 사용하여 510 nm(플라보노이드)에서 측정하였다.The total polyphenol and flavonoid contents of the extracts of the roots, stems, leaves and fruits of Black Rooster prepared in Example 1 were measured using Folin-Ciocalteu (total polyphenols) and aluminum chloride (flavonoids) colorimetric methods. Absorbance was measured at 700 nm (total polyphenols) using an Ultrospec 6300 Pro (GE Healthcare Life Sciences, Buckinghamshire, UK) and at 510 nm (flavonoids) using a VICTOR Multilabel Plate Reader (Perkin-Elmer, Waltham, MA, USA). ) was measured.
갈산(총 폴리페놀)과 케르세틴(플라보노이드)을 표준으로 하여 표준곡선을 작성하였고, 그 결과를 흑노호 뿌리, 줄기, 잎, 열매 추출물의 그램당 갈산 당량(GAE/g)과 그램당 케르세틴 당량(QE/g)으로 나타내었다. A standard curve was prepared using gallic acid (total polyphenols) and quercetin (flavonoids) as standards. QE/g).
총페놀 함량 분석 결과, 도 1B와 같이 흑노호 뿌리 추출물(197.6 ± 27.2 mg GAE/g)이 가장 높은 페놀 함량을 보였고, 흑노호 잎 추출물(153.7 ± 6.7 mg GAE/g)과 흑노호 줄기 추출물(88.1 ± 7.8 mg GAE/g)이 그 뒤를 이었고, 흑노호 열매 추출물(21.8 ± 4.8 mg GAE/g)은 페놀 함량이 가장 낮았다. As a result of analyzing the total phenol content, as shown in FIG. 1B, the black roe deer root extract (197.6 ± 27.2 mg GAE / g) showed the highest phenol content, and the black roe deer leaf extract (153.7 ± 6.7 mg GAE / g) and the black roe deer stem extract ( 88.1 ± 7.8 mg GAE/g) followed, followed by black roe fruit extract (21.8 ± 4.8 mg GAE/g) with the lowest phenol content.
또한, 플라보노이드 함량 분석 결과, 도 1C와 같이 흑노호 잎 추출물(94.5 ± 6.3 mg QE/g)이 가장 높은 플라보노이드 함량을 보였고, 흑노호 뿌리 추출물(79.6 ± 4.2 mg QE/g)이 그 뒤를 이었고, 흑노호 줄기 추출물(14.9 ± 1.3 mg QE/g) 및 흑노호 열매 추출물(6.4 ± 2.0 mg QE/g)은 플라보노이드 함량이 가장 낮았다. In addition, as a result of flavonoid content analysis, as shown in FIG. 1C, the black roe deer leaf extract (94.5 ± 6.3 mg QE / g) showed the highest flavonoid content, followed by the black roe deer root extract (79.6 ± 4.2 mg QE / g), Black oenophila stem extract (14.9 ± 1.3 mg QE/g) and black oenophile fruit extract (6.4 ± 2.0 mg QE/g) had the lowest flavonoid content.
<실시예 3> DPPH 및 ABTS 분석<Example 3> DPPH and ABTS analysis
실시예 1에서 준비된 흑노호 뿌리, 줄기, 잎 및 열매 추출물(0.5 mg/mL)의 DPPH 및 ABTS 라디칼 소거 활성은 이전에 알려진 방법[Nanomaterials 2020, 10, 1350]에 따라 약간 변형하여 측정되었다. 흑노호 뿌리, 줄기, 잎 및 열매 추출물(0.5 mg/mL)을 마이크로플레이트에서 DPPH 용액(60 μM)과 혼합하였다. 시료를 세게 흔든 후 30분 동안 25℃의 암실에 보관하였다. 7mM ABTS 및 2.6mM 과황산칼륨의 스톡 용액을 18시간 동안 암실에서 실온에서 증류수에서 제조하였다. 흑노호 뿌리, 줄기, 잎 및 열매 추출물(0.5 mg/mL)을 상기 제조한 용액에 혼합한 다음 암소에서 실온에서 30분 동안 방치하였다. 시료 반응물의 흡광도는 510 nm (DPPH) 또는 734 nm (ABTS)에서 모니터링 되었다.The DPPH and ABTS radical scavenging activities of the extracts (0.5 mg/mL) of the roots, stems, leaves and fruits of black roe deer prepared in Example 1 were measured according to a previously known method [Nanomaterials 2020, 10, 1350] with slight modifications. Black roe root, stem, leaf and fruit extracts (0.5 mg/mL) were mixed with DPPH solution (60 μM) in a microplate. After shaking the sample vigorously, it was stored in the dark at 25°C for 30 minutes. A stock solution of 7 mM ABTS and 2.6 mM potassium persulfate was prepared in distilled water at room temperature in the dark for 18 hours. Extracts (0.5 mg/mL) of roots, stems, leaves, and fruits of black oatmeal were mixed with the above-prepared solution, and then left in the dark at room temperature for 30 minutes. The absorbance of the sample reactants was monitored at 510 nm (DPPH) or 734 nm (ABTS).
도 1D와 같이, 흑노호 잎 추출물(94.7±2.9%)과 흑노호 뿌리 추출물(82.8±5.9%)이 가장 높은 ABTS 라디칼 소거 활성을 보였고, 흑노호 줄기 추출물(29.7±2.0%)과 흑노호 열매 추출물(15.9±2.0%)이 그 뒤를 이었다. 도 1E와 같이, DPPH 라디칼 소거 활성도 흑노호 잎 추출물(99.9 ± 0.1%) > 흑노호 뿌리 추출물(95.5 ± 3.6%) > 흑노호 줄기 추출물(25.7 ± 2.1%) > 흑노호 열매 추출물(8.7 ± 1.1%)의 순서로 나타났다.As shown in Figure 1D, the black roe leaf extract (94.7 ± 2.9%) and black roe root extract (82.8 ± 5.9%) showed the highest ABTS radical scavenging activity, and the black roe stem extract (29.7 ± 2.0%) and black roe roe fruit Extract (15.9±2.0%) followed. As shown in Figure 1E, the DPPH radical scavenging activity of black roe deer leaf extract (99.9 ± 0.1%) > black roe deer root extract (95.5 ± 3.6%) > black roe deer stem extract (25.7 ± 2.1%) > black roe deer fruit extract (8.7 ± 1.1%) %) in order.
<실시예 4> 흑노호 추출물의 피부 광보호 효과 검토<Example 4> Examination of the skin photoprotection effect of the black oatmeal extract
1. 세포배양1. Cell culture
부착된 각질세포(HaCaT)를 10% FBS(Invitrogen Corporation, Carlsbad, CA, USA) 및 1% 페니실린/스트렙토마이신(Invitrogen Corporation, Carlsbad, CA, USA)를 포함한 DMEM (Invitrogen Corporation, Carlsbad, CA, USA) 배지 용액에 접종하고, 37℃에서 5% CO2로 배양하였다. 부착된 HaCaT 세포의 성장을 정기적으로 관찰하였고, 배지는 2-3일마다 교체하였다. 대수 성장 단계의 세포를 후속 실험에 사용하였다.Adherent keratinocytes (HaCaT) were cultured in DMEM (Invitrogen Corporation, Carlsbad, CA, USA) containing 10% FBS (Invitrogen Corporation, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Invitrogen Corporation, Carlsbad, CA, USA). ) and inoculated into the medium solution, and incubated at 37°C with 5% CO 2 . The growth of adherent HaCaT cells was observed regularly, and the medium was changed every 2-3 days. Cells in logarithmic growth phase were used for subsequent experiments.
2. UVA and UVB 조사2. UVA and UVB irradiation
각질세포는 365 nm(UVA) 또는 312 nm(UVB)의 방출 피크에서 대부분의 에너지를 방출하는 5 ㅧ 8 W 튜브를 사용하여 UVA 또는 UVB 조사(Bio-Link BLX-365, Villber-Lourmat, Eberhardzell, Germany)에 노출되었고, UVA 조사량은 20 J/cm2이고 UVB 조사량은 50 mJ/cm2이었다.Keratinocytes were irradiated with UVA or UVB (Bio-Link BLX-365, Villber-Lourmat, Eberhardzell, Germany), the UVA dose was 20 J/cm 2 and the UVB dose was 50 mJ/cm 2 .
3. 세포 생존력 및 세포독성 분석3. Cell viability and cytotoxicity assay
세포 생존력 분석을 위해 CCK-8 Assay Kit(Sigma-Aldrich, St. Louis, MO, USA)의 Cell Counting Kit-8(CCK-8) 용액을 제조업체의 지침에 따라 HaCaT 각질세포 현탁액에 첨가하고 37℃에서 4시간 동안 배양하였다. 즉, 2x104 세포를 24웰 플레이트의 각 웰에 분주하고 37, 5% CO2에서 24시간 동안 배양하였다. 24시간 배양 후, CCK-8 시약을 각 웰에 첨가하고, 세포를 4시간 동안 추가로 배양하였다. 세포독성 검출 키트(Roche Applied Science, Switzerland)를 사용하여 HaCaT 각질세포 배양 배지에서 세포외 젖산 탈수소효소(LDH) 방출을 측정하였다. VICTOR Multilabel Plate Reader를 사용하여 450 nm (CCK-8) 및 490 nm (LDH)에서 흡광도를 분석하였다.For cell viability assay, Cell Counting Kit-8 (CCK-8) solution from CCK-8 Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) was added to the HaCaT keratinocyte suspension according to the manufacturer's instructions and incubated at 37 °C. incubated for 4 hours. That is, 2x10 4 cells were dispensed into each well of a 24-well plate and cultured for 24 hours at 37, 5% CO 2 . After 24 hours of incubation, CCK-8 reagent was added to each well and cells were further cultured for 4 hours. Extracellular lactate dehydrogenase (LDH) release was measured in HaCaT keratinocyte culture medium using a cytotoxicity detection kit (Roche Applied Science, Switzerland). Absorbance was analyzed at 450 nm (CCK-8) and 490 nm (LDH) using a VICTOR Multilabel Plate Reader.
CCK-8 분석 결과, 도 2A와 같이 흑노호 추출물은 0.5 mg/mL 농도에서 각질세포 생존율을 유의하게 변화시키지 않는 것으로 나타났고, UVA 또는 UVB 조사가 있는 상태에서는 각질세포 생존력을 유의하게 억제하였으나, 흑노호 부위별 추출물 처리에 의해 각질세포의 생존력이 증가하였다. As a result of CCK-8 analysis, as shown in FIG. 2A, it was found that the black roe extract did not significantly change keratinocyte viability at a concentration of 0.5 mg/mL, and significantly inhibited keratinocyte viability in the presence of UVA or UVB irradiation. The viability of keratinocytes was increased by the treatment of extracts from each part of black oatmeal.
또한, 세포 외 LDH 방출 측정 결과, 도 2B와 같이 UVA 또는 UVB 조사가 LDH 방출을 상당히 촉진하였으나, 흑노호 부위별 추출물 처리에 의해 UVA 또는 UVB 노출로 야기된 LDH 방출을 크게 약화시켰다. In addition, as a result of measuring extracellular LDH release, UVA or UVB irradiation significantly promoted LDH release as shown in FIG.
이러한 결과로부터, 흑노호 잎 추출물, 흑노호 뿌리 추출물, 흑노호 줄기 추출물 및 흑노호 열매 추출물 순으로 각질세포에 대한 UVA 또는 UVB 조사로 유발된 항증식 및 세포독성 효과가 완화됨을 확인하였다. 특히, 흑노호 잎 추출물은 세포 생존 능력을 제어 수준으로 복원할 수 있었다.From these results, it was confirmed that the anti-proliferative and cytotoxic effects induced by UVA or UVB irradiation on keratinocytes were alleviated in the order of black roe leaf extract, black roe deer root extract, black roe deer stem extract, and black roe deer fruit extract. In particular, the black oenophile leaf extract was able to restore cell viability to a controlled level.
4. 각질세포에서 세포내 ROS 생성 평가4. Assessment of intracellular ROS production in keratinocytes
세포내 ROS 수준은 5-(and-6)-클로로메틸-2',7'-디클로로디히드로플루오레세인 디아세테이트 아세틸 에스테르(CM-H2DCFDA; Thermo Fisher Scientific, Waltham, MA, USA)를 사용하여 분석하였다. 모든 절차는 제조업체의 지침에 따라 수행하였다. 즉, 흑노호 부위별 추출물(0.5 mg/mL) 처리 후, 각질세포(HaCaT)를 인산완충식염수(PBS)로 세척하고 CM-H2DCFDA(5 μM)와 함께 어둠 속에서 30분 동안 배양하였다. 그 후, Carl Zeiss 형광 현미경을 사용하여 세포내 ROS의 생성을 시각화 하였다. 형광 강도는 유세포 분석기(Fit NXT Flow Cyto, Thermo Fisher Scientific, Pasadena, CA, USA)를 사용하여 형광 염료(CM-H2DCFDA)를 기반으로 측정되었다.Intracellular ROS levels were measured by 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H 2 DCFDA; Thermo Fisher Scientific, Waltham, MA, USA). analyzed using All procedures were performed according to the manufacturer's instructions. That is, after treatment with the extract (0.5 mg/mL) of each part of black oenophile, the keratinocytes (HaCaT) were washed with phosphate buffered saline (PBS) and incubated with CM-H 2 DCFDA (5 μM) for 30 minutes in the dark. . Then, the production of intracellular ROS was visualized using a Carl Zeiss fluorescence microscope. Fluorescence intensity was measured based on a fluorescent dye (CM-H 2 DCFDA) using a flow cytometer (Fit NXT Flow Cyto, Thermo Fisher Scientific, Pasadena, CA, USA).
형광 현미경 분석 결과, 도 3A와 같이 UVA 또는 UVB 조사에 의해 각질세포에서 상당한 염색을 보였으나, 흑노호 부위별 추출물 처리에 의해 세포내 ROS 수준이 억제됨을 확인하였다.As a result of fluorescence microscopic analysis, as shown in FIG. 3A, significant staining was shown in keratinocytes by UVA or UVB irradiation, but it was confirmed that the intracellular ROS level was suppressed by treatment with extracts of each part of black oatmeal.
유세포 분석의 정량화된 결과에 따르면, 도 3B와 같이 UVA 및 UVB 조사는 대조군(5.7 ± 0.2%)에 비해 각질세포의 세포내 ROS 수준을 각각 27.2 ± 4.5% 및 34.1 ± 4.2% 증가시켰고, 흑노호 잎 추출물, 흑노호 뿌리 추출물, 흑노호 줄기 추출물 및 흑노호 열매 추출물 순으로 세포내 ROS 수준이 억제됨을 확인하였다. According to the quantified results of flow cytometry, as shown in FIG. 3B, UVA and UVB irradiation increased the intracellular ROS level of keratinocytes by 27.2 ± 4.5% and 34.1 ± 4.2%, respectively, compared to the control group (5.7 ± 0.2%), and It was confirmed that the intracellular ROS level was inhibited in the order of leaf extract, black oenophila root extract, black oenophile stem extract, and black oko fruit extract.
이러한 결과로부터, 흑노호 추출물, 특히 흑노호 잎 추출물은 내인성 ROS 수준을 감소시켜 각질세포 손상을 유의하게 억제하였음을 나타낸다.From these results, it is shown that the black oenophila extract, in particular, the black oenophile leaf extract, significantly inhibited keratinocyte damage by reducing the level of endogenous ROS.
5. 세포자멸사 분석5. Apoptosis assay
UV 노출 및 흑노호 추출물 처리 후 HaCaT 각질세포를 트립신 처리하고 원심분리한 후, 제조사의 지시에 따라 fluorescein isothiocyanate (FITC) Annexin V/Dead Cell Apoptosis Kit (Invitrogen Life Technologies, Carlsbad, CA, USA)를 사용하여 얻어진 세포의 세포사멸을 평가하였다. 즉, 각질세포를 PBS로 2회 헹구고 아넥신 결합 완충액에서 각질 세포를 얻고 FITC/아넥신 V(성분 A) 및 요오드화 프로피디움(PI) 작업 용액과 혼합하였다. 실온에서 15분 동안 암실에서 배양한 후, 각질세포 세포자멸사를 측정하고 유세포분석기(Fit NXT Flow Cyto, Thermo Fisher Scientific, Pasadena, CA, USA)를 사용하여 세포자멸사 세포의 백분율을 계산하였다. FL1(FITC/Nexin V) 및 FL3(PI) 채널에 대한 신호를 감지하고 사분면 마커 염색 및 염색된 세포의 도트 플롯을 설정하였다.After UV exposure and black roe extract treatment, HaCaT keratinocytes were trypsinized and centrifuged, and then fluorescein isothiocyanate (FITC) Annexin V/Dead Cell Apoptosis Kit (Invitrogen Life Technologies, Carlsbad, CA, USA) was used according to the manufacturer's instructions. Apoptosis of the obtained cells was evaluated. That is, keratinocytes were rinsed twice with PBS, and keratinocytes were obtained in annexin binding buffer and mixed with FITC/Annexin V (component A) and propidium iodide (PI) working solution. After incubation in the dark at room temperature for 15 minutes, keratinocyte apoptosis was measured and the percentage of apoptotic cells was calculated using a flow cytometer (Fit NXT Flow Cyto, Thermo Fisher Scientific, Pasadena, CA, USA). Signals for the FL1 (FITC/Nexin V) and FL3 (PI) channels were detected and quadrant marker staining and dot plots of the stained cells were set up.
도 4A와 같이, UVA 및 UVB 조사는 Annexin V 염색 활성을 촉진한 반면, 흑노호 부위별 추출물이 UVA 및 UVB 조사에 따른 Annexin V 염색 활성 속도를 감소시켰다. UVA 및 UVB 조사 없이 흑노호 부위별 추출물 단독(0.5 mg/mL) 처리는 Annexin V 염색 활성을 유도하지 않았다. As shown in FIG. 4A, UVA and UVB irradiation promoted Annexin V staining activity, whereas extracts from parts of black oatmeal reduced the Annexin V staining activity rate according to UVA and UVB irradiation. Annexin V staining activity was not induced by treatment with the extract alone (0.5 mg/mL) from each part of the black roe deer without UVA and UVB irradiation.
도 4B와 같이, 유세포 분석기의 정량화된 데이터는 UVA 및 UVB 조사가 대조군(5.0% ± 0.7%)에 비해 각질세포의 세포자멸사 수준을 각각 46.3 ± 1.5% 및 48.7 ± 1.0% 증가시켰으나, UVA 또는 UVB 조사 조건에서 흑노호 부위별 추출물 처리에 의해 흑노호 잎 추출물, 흑노호 뿌리 추출물, 흑노호 줄기 추출물 및 흑노호 열매 추출물 순으로 세포사멸 수준이 억제되었음을 확인하였다As shown in Figure 4B, the quantified data of flow cytometry showed that UVA and UVB irradiation increased the apoptosis level of keratinocytes by 46.3 ± 1.5% and 48.7 ± 1.0%, respectively, compared to the control group (5.0% ± 0.7%), but neither UVA nor UVB It was confirmed that the level of apoptosis was suppressed in the order of black roe leaf extract, black roe root extract, black roe stem extract, and black roe fruit extract by treatment with extracts of each part of black roe deer under irradiation conditions.
하기에 본 발명에 따른 흑노호 잎 추출물(KCL)을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of a composition containing the black roe deer leaf extract (KCL) according to the present invention will be described, but the present invention is not intended to limit this, but only to be specifically described.
<제제예 1> 약학조성물의 처방예<Formulation Example 1> Prescription example of pharmaceutical composition
<제제예 1-1> 산제의 제조<Formulation Example 1-1> Preparation of powder
KCL 20 mg, 유당 100 mg 및 탈크 10 mg을 혼합하고 기밀포에 충진하여 산제를 제조하였다.A powder was prepared by mixing 20 mg of KCL, 100 mg of lactose, and 10 mg of talc and filling in an airtight bag.
<제제예 1-2> 정제의 제조<Formulation Example 1-2> Manufacture of tablets
KCL 10 mg, 옥수수전분 100 mg, 유당 100 mg 및 스테아린산 마그네슘 2 mg을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.Tablets were prepared by mixing 10 mg of KCL, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate, and then tableting according to a conventional tablet manufacturing method.
<제제예 1-3> 캅셀제의 제조<Formulation Example 1-3> Preparation of capsule formulation
KCL 10 mg, 옥수수전분 100 mg, 유당 100 mg 및 스테아린산 마그네슘 2 mg을 혼합한 후 통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing 10 mg of KCL, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate, the above ingredients were mixed according to a conventional capsule preparation method and filled into gelatin capsules to prepare capsules.
<제제예 1-4> 주사제의 제조<Formulation Example 1-4> Preparation of injection
KCL 10 mg, 주사용 멸균 증류수 적량 및 pH 조절제 적량을 혼합한 후 통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조하였다.After mixing 10 mg of KCL, an appropriate amount of sterilized distilled water for injection, and an appropriate amount of a pH adjusting agent, the above ingredient content was prepared per 1 ampoule (2 ml) according to a conventional method for preparing an injection.
<제제예 2> 건강보조식품<Formulation Example 2> Health Supplement
<제제예 2-1> 건강식품의 제조<Formulation Example 2-1> Manufacture of health food
KCL 1 ㎎, 비타민 혼합물 적량(비타민 A 아세테이트 70 ㎍, 비타민 E 1.0 ㎎, 비타민 B1 0.13 ㎎, 비타민 B2 0.15 ㎎, 비타민 B6 0.5 ㎎, 비타민 B12 0.2 ㎍, 비타민 C10 ㎎, 비오틴 10 ㎍, 니코틴산아미드 1.7 ㎎, 엽산 50 ㎍, 판토텐산 칼슘 0.5 ㎎) 및 무기질 혼합물 적량(황산 제1철 1.75 ㎎, 산화아연 0.82 ㎎, 탄산마그네슘 25.3 ㎎, 제1인산칼륨 15 ㎎, 제2인산칼슘 55 ㎎, 구연산칼륨 90 ㎎, 탄산칼슘 100 ㎎, 염화마그네슘 24.8 ㎎)을 혼합한 다음 과립을 제조하고 통상의 방법에 따라 건강식품을 제조하였다.KCL 1 mg, appropriate amount of vitamin mixture (vitamin A acetate 70 μg, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 μg, vitamin C 10 mg, biotin 10 μg, nicotinamide 1.7 mg, folic acid 50 μg, calcium pantothenate 0.5 mg) and appropriate amount of mineral mixture (ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, monopotassium phosphate 15 mg, dicalcium phosphate 55 mg, potassium citrate 90 mg, calcium carbonate 100 mg, and magnesium chloride 24.8 mg) were mixed, then granules were prepared and health food was prepared according to a conventional method.
<제제예 2-2> 건강음료의 제조<Formulation Example 2-2> Manufacture of health drink
KCL 1 ㎎, 구연산 1000 ㎎, 올리고당 100 g, 매실농축액 2 g, 타우린 1 g 및 정제수를 가하여 전체 900 ㎖가 되도록 하며, 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하였다. Add 1 mg of KCL, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, 1 g of taurine, and purified water to make a total of 900 ml. After heating while stirring at 85 ° C., the resulting solution was filtered and collected in a sterilized 2 L container, sealed and sterilized, and stored in a refrigerator.
<제제예 3> 화장료 조성물<Formulation Example 3> Cosmetic composition
<제제예 3-1> 스킨로션의 제조<Formulation Example 3-1> Manufacture of skin lotion
프로필렌글리콜 3.0 중량부, 카르복시폴리머 0.1 중량부, 방부제 미량과 잔량의 정제수를 혼합교반하면서 80 내지 85℃로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 폴리솔베이트60 1.0 중량부, 솔비탄 세스퀴올레이트 0.5 중량부, 유동 파라핀 10.0 중량부, 솔비탄 스테아레이트 1.0 중량부, 친유형 모노스테아린산 글리세린 0.5 중량부, 스테아린산 1.5 중량부, 글리세릴스테아레이트/PEG-400 스테아레이트 1.0 중량부, 트리에탄올아민 0.2 중량부를 80 내지 85℃로 가열하여 투입한 뒤 유화하였다. 유화가 끝나면 교반기를 이용하여 교반하면서 50℃까지 열 냉각한 뒤 향료 미량을 투입하고, 45℃까지 냉각한 뒤 색소 미량을 투입하고, 35℃에서 KCL을 투입하여 25℃까지 냉각한 뒤 숙성시켰다.3.0 parts by weight of propylene glycol, 0.1 part by weight of carboxypolymer, a small amount of preservative and the remaining amount of purified water are heated to 80 to 85 ° C. while mixing and stirring, and then introduced into the manufacturing unit, and then an emulsifier is operated, and polysorbate 60 1.0 part by weight, sorbitan Sesquioleate 0.5 parts by weight, liquid paraffin 10.0 parts by weight, sorbitan stearate 1.0 parts by weight, lipophilic monostearate glycerin 0.5 parts by weight, stearic acid 1.5 parts by weight, glyceryl stearate / PEG-400 stearate 1.0 parts by weight, triethanol After adding 0.2 parts by weight of amine by heating to 80 to 85 ℃, it was emulsified. After emulsification was completed, heat-cooled to 50 ° C while stirring using a stirrer, then added a trace amount of fragrance, cooled to 45 ° C, added a trace amount of pigment, added KCL at 35 ° C, cooled to 25 ° C, and aged.
<처방예 2-2> 영양크림의 제조<Formulation Example 2-2> Preparation of nutrient cream
카르복시폴리머 0.3 중량부, 부틸렌글리콜 5.0 중량부, 글리세린 3.0 중량부 및 잔량의 정제수를 혼합교반하면서 80 내지 85℃로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 스테아린산 2.0 중량부, 세틸알콜 2.0 중량부, 글리세릴모노스테아레이트 2.0 중량부, 폴리옥시에틸렌솔비탄모노스테아레이트 0.5 중량부, 솔비탄세스퀴올레이트 0.5 중량부, 글리세릴모노스테아레이트/글리세릴스테아레이트/폴리옥시에틸렌스테아레이트 1.0 중량부, 왁스 1.0 중량부, 유동파라핀 4.0 중량부, 스쿠알란 4.0 중량부, 카프릴릭/카프릭트리글리세라이드 4.0 중량부를 80 내지 85℃로 가열하여 투입한 뒤 트리에탄올아민 0.5 중량부를 투입하여 유화하였다. 유화가 끝나면 교반기를 이용하여 교반하면서 35℃까지 냉각한 뒤 KCL을 투입하여 25℃까지 냉각한 뒤 숙성시켰다.0.3 parts by weight of carboxypolymer, 5.0 parts by weight of butylene glycol, 3.0 parts by weight of glycerin, and the remaining amount of purified water were heated to 80 to 85 ° C. while mixing and stirring, and then introduced into the manufacturing unit, and then an emulsifier was applied, and 2.0 parts by weight of stearic acid and cetyl alcohol 2.0 parts by weight, 2.0 parts by weight of glyceryl monostearate, 0.5 parts by weight of polyoxyethylene sorbitan monostearate, 0.5 parts by weight of sorbitan sesquioleate, glyceryl monostearate/glyceryl stearate/polyoxyethylene stearate 1.0 parts by weight of wax, 1.0 parts by weight of wax, 4.0 parts by weight of liquid paraffin, 4.0 parts by weight of squalane, and 4.0 parts by weight of caprylic/capric triglyceride were added by heating to 80 to 85° C., followed by emulsification by adding 0.5 parts by weight of triethanolamine. . After emulsification was completed, the mixture was cooled to 35 ° C while stirring using a stirrer, and then cooled to 25 ° C by introducing KCL and aged.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시예일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Having described specific parts of the present invention in detail above, it will be clear to those skilled in the art that these specific descriptions are merely preferred embodiments, and the scope of the present invention is not limited thereby. will be. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220005067A KR20230109286A (en) | 2022-01-13 | 2022-01-13 | Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220005067A KR20230109286A (en) | 2022-01-13 | 2022-01-13 | Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230109286A true KR20230109286A (en) | 2023-07-20 |
Family
ID=87426484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220005067A KR20230109286A (en) | 2022-01-13 | 2022-01-13 | Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230109286A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116831928A (en) * | 2023-08-24 | 2023-10-03 | 新晃县九州农业综合开发有限公司 | Propionibacterium acnes-inhibiting composition containing natural borneol and application of composition in cosmetics |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102011240B1 (en) | 2019-01-31 | 2019-08-14 | 에스케이바이오랜드 주식회사 | Novel Lactobacillus paracasei SKB1192 strain and its products with light protection |
-
2022
- 2022-01-13 KR KR1020220005067A patent/KR20230109286A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102011240B1 (en) | 2019-01-31 | 2019-08-14 | 에스케이바이오랜드 주식회사 | Novel Lactobacillus paracasei SKB1192 strain and its products with light protection |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116831928A (en) * | 2023-08-24 | 2023-10-03 | 新晃县九州农业综合开发有限公司 | Propionibacterium acnes-inhibiting composition containing natural borneol and application of composition in cosmetics |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101251040B1 (en) | Manufacturing method and cosmetic ingredient using Dendropanax morbifera Lev extraction fluid | |
KR20210087405A (en) | Compositions Containing Plant Extracts | |
KR101132572B1 (en) | Skin Whitening Composition | |
KR101839407B1 (en) | Composition comprising actinidia polygama extract for improving skin whitening or wrinkle | |
KR101402550B1 (en) | Antioxidizing Functional Cosmetic Compositions for Containing Extracted/Fermented Dendropanax morbifera Products and Functional Cosmetics Produced Thereby | |
KR102253376B1 (en) | Composition for improving winkle or skin whitening comprising atriplex gmelinii extract or paederia scandens extract | |
KR101467627B1 (en) | UV-induced Apoptosis in human Keratinocytes Suppressing Composition Containing Extract of Undaria crenata | |
KR20230109286A (en) | Composition for protecting photo-damaged skin comprising extract of Kadsura coccinea | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
CN106413687A (en) | Product containing Rhodiola extract and Ginkgo biloba extract, and preparation method and use thereof | |
KR101551106B1 (en) | A composition comprising the extract of Paspalum thunbergii Kunth | |
KR101861094B1 (en) | Composition for improving wrinkles containing plant extract | |
KR102577528B1 (en) | Composition for improving skin | |
KR20130136753A (en) | Cosmetic composition comprising cercis chinensis or reynoutria japonica for. elata extract for skin whitening | |
KR102011639B1 (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
KR101069906B1 (en) | A composition for improving skin conditions comprising extract of Aster subulatus Michx. | |
KR101592117B1 (en) | A composition comprising the extract of Geranuium eriostemon | |
KR102489463B1 (en) | Composition for whitening comprising extract of microwave treated Dendropanax morbifera | |
KR102334192B1 (en) | Functional cosmetic composition comprising korean dandelion | |
KR20110013238A (en) | Melanogenesis inhibitor and skin-whitening agent | |
KR102214765B1 (en) | Cosmetic composition for skin whitening and anti-wrinkle containing extracts of herb mixture | |
KR102553245B1 (en) | Composition for antioxidant or inhibiting aging comprising Prunus mume f. viridicalyx extract | |
KR100831092B1 (en) | Skin whitening composition containing celastrus orbiculatus extract |